NEW YORK, Jan. 9, 2018 /PRNewswire/ -- The global market for cardiovascular devices reached nearly $42.4 billion in 2017 and should reach $59.1 billion by 2022, at a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.

• Interventional cardiology devices as a segment reached nearly $15.4 billion in 2017 and should reach $22.5 billion by 2022 at a CAGR of 8.0% through 2022.
• Cardiac rhythm management devices as a segment reached nearly $14.0 billion in 2017 and should reach $19.8 billion by 2022 at a CAGR of 7.2% through 2022.


Study Goals and Objectives
The goals of this study are, to quantify the market for various segments of the cardiovascular devices market, to explore market dynamics such as drivers and restraints, to study the recent advancements/innovations available in the market, to identify the areas of growth within the cardiovascular devices market, and to identify the factors affecting the market affecting the manufacture of cardiovascular devices.

Reasons for Doing This Study
Cardiovascular devices (CVD) help in monitoring and treating various disorders associated with cardiovascular systems. The global cardiovascular devices industry is a diverse and highly competitive market. The market is driven majorly by rising global burden of cardiac diseases, growing geriatric population, and technological advancements. The cardiac diagnostic and therapeutic products and services will continue to rise, providing opportunities for existing, emerging market participants and very new entrants.

The advances in both interventional and non-interventional devices like electrocardiogram (ECG) devices, Holter monitors, diagnostic catheters, and implantable cardiac monitors has opened several opportunities for the investors. The use of big data, the integration of smartphones and wearable devices into patient care, robots in the cath lab, and 3-D printing have their potential impact on the CVD market. Innovations such as minimally invasive procedures, "beating heart" surgeries, ventricular assist devices and artificial hearts, replacement valves and treatments for hypertension such as renal denervation offer therapeutic options that result in shorter recovery times and reduced complication risks. Newer diagnostic cardiovascular devices and therapeutic techniques will play an increasing role in enhancing quality of life for a growing elderly population, as well as patient groups with poor cardiac function. The ability of government-run health agencies and private insurance providers to cope with the increased need for cardiovascular procedures, together with rising healthcare costs, have led agencies and insurers to closely evaluate their coverage for cardiovascular surgical procedures and continually seek out lower-cost but still efficacious options.

Cardiology Homepage